News Orders & Deals OneSource Specialty Pharma Receives Stock Exchange Approval for Multi-Entity Merger SchemeOneSource Specialty Pharma Receives Stock Exchange Approval for Multi-Entity Merger Scheme
OneSource Specialty Pharma Limited has received no objection letters from NSE and BSE on February 25, 2026, for its composite scheme of arrangement involving merger of multiple entities including Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, and Strides Pharma Services Private Limited. The approval is valid for six months and comes with extensive SEBI compliance requirements including detailed shareholder disclosures and financial transparency measures. The scheme remains subject to additional approvals from NCLT Mumbai, Singapore Court, and respective shareholders and creditors.
*this image is generated using AI for illustrative purposes only.
OneSource Specialty Pharma Limited has secured crucial regulatory approval for its ambitious merger plan, receiving no objection letters from both the National Stock Exchange of India Limited and BSE Limited on February 25, 2026. The approval relates to a comprehensive composite scheme of arrangement and amalgamation involving multiple entities that will significantly reshape the company's structure.
Merger Structure and Entities Involved
The proposed scheme encompasses a complex multi-entity merger involving several companies. The arrangement includes the amalgamation of Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, and Strides Pharma Services Private Limited with OneSource Specialty Pharma Limited. This merger by absorption will consolidate operations across multiple jurisdictions, including provisions under both Indian Companies Act and Singapore Companies Act.
| Parameter: | Details |
|---|---|
| Approval Date: | February 25, 2026 |
| Validity Period: | Six months from issue date |
| Regulatory Framework: | Sections 230-232, 234, 52, 66 of Companies Act 2013 |
| International Compliance: | Singapore Companies Act Section 210-212 |
| Board Approval Date: | September 26, 2025 |
SEBI Compliance Requirements
The stock exchange approval comes with extensive compliance obligations mandated by SEBI. The regulatory body has outlined comprehensive disclosure requirements that OneSource must fulfill before proceeding with the merger. Key compliance areas include ensuring adherence to Regulation 11 of SEBI LODR Regulations 2015 and providing detailed information about ongoing legal proceedings against the company, its promoters, and directors.
The company must prominently disclose shareholding pattern changes on the first page of shareholder meeting notices, including pre-scheme and post-scheme shareholding percentages for both promoter groups and public shareholders. Additional requirements include disclosing accumulated losses of transferor entities, impact on reserves, and comprehensive details about the merger's rationale and benefits.
Financial and Operational Disclosures
SEBI has mandated extensive financial disclosures as part of the approval process. OneSource must provide detailed information about assets, liabilities, net worth, and revenue of all companies involved in the merger, both pre and post-scheme implementation. The company is required to disclose the impact on revenue generating capacity and provide comprehensive cost-benefit analysis of the proposed arrangement.
| Disclosure Requirement: | Details |
|---|---|
| Financial Updates: | Latest financials not older than 6 months |
| Valuation Details: | Registered valuer and merchant banker information |
| Share Swap Ratio: | Complete methodology and rationale |
| Growth Projections: | Justification for valuation growth rates |
| Risk Assessment: | Benefits, risks, and integration challenges |
Regulatory Timeline and Next Steps
The no objection letters carry a validity period of six months from February 25, 2026, within which OneSource must submit the scheme to the National Company Law Tribunal. The company has committed to placing these approval letters before the Board of Directors of all involved companies for review and decision on the implementation pathway.
The merger scheme remains subject to several additional approvals, including clearance from Hon'ble National Company Law Tribunal Mumbai, Singapore Court, and approval from respective shareholders and creditors under applicable laws. OneSource must also ensure compliance with various SEBI master circulars and maintain transparency through regular updates on company and stock exchange websites.
Shareholder Communication Requirements
As part of the approval conditions, OneSource must provide comprehensive information to shareholders to enable informed decision-making. This includes detailed explanations of how the merger benefits public shareholders, particularly considering that accumulated losses from transferor entities will become part of OneSource's balance sheet. The company must also disclose potential integration challenges, market conditions, and financial uncertainties associated with the merger.
The stock exchanges have reserved their rights to withdraw approval if any submitted information is found incomplete, incorrect, misleading, or false, or for any contravention of exchange rules and regulations. OneSource has uploaded the approval letters on its website and will continue to provide updates as the merger process progresses through the remaining regulatory approvals.
Historical Stock Returns for Onesource Specialty Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.31% | -0.82% | -7.66% | -29.78% | -1.93% | -22.65% |
16
